Coeptis director exercises options, gets stock grant

Coeptis Therapeutics Holdings director Chris Calise increased his holdings through an option exercise and a stock grant.

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings director Chris Calise increased his holdings through an option exercise and a stock grant. On 02/11/2026 he acquired 5,700 shares of common stock by exercising stock options at $10.56 per share and received 3,250 shares of restricted stock for no cash cost in connection with an option exchange program. Following these transactions, he beneficially owns 368,741 shares of common stock, including 49,500 shares held by CJC Investment Trust and 47,106 shares issuable under currently exercisable warrants.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Calise Chris

Role Director

Type	Security	Shares	Price	Value
Exercise	Common stock	5,700	$10.56	$60K
Grant/Award	Common stock	3,250	$0.00	$0.00

Holdings After Transaction: Common stock — 368,741 shares (Direct)

Footnotes (3)

1. F1. Represents the exercise price of shares purchased upon exercise of stock options.
2. F2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.
3. F3. Includes (i) 49,500 shares of common stock that are owned by CJC Investment Trust (a Trust in which Mr. Calise is a control person), and (ii) 47,106 shares of common stock that are issuable under currently exercisable warrants.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Coeptis Therapeutics (COEP) director Chris Calise report?

Chris Calise reported acquiring common stock in Coeptis Therapeutics through an option exercise and a restricted stock grant. On 02/11/2026 he exercised stock options for 5,700 shares and received 3,250 restricted shares issued under an option exchange program.

How many Coeptis Therapeutics (COEP) shares did Chris Calise acquire via option exercise?

Chris Calise acquired 5,700 shares of Coeptis Therapeutics common stock by exercising stock options at an exercise price of $10.56 per share. This transaction is coded as an exercise or conversion of a derivative security, not as an open-market stock purchase.

What is the restricted stock grant reported by Coeptis Therapeutics (COEP) director Chris Calise?

Chris Calise received a grant of 3,250 shares of restricted common stock with a price of $0. The grant was issued in connection with an option exchange program where he surrendered underwater options in exchange for restricted stock in Coeptis Therapeutics.

How many Coeptis Therapeutics (COEP) shares does Chris Calise beneficially own after these transactions?

After the reported transactions, Chris Calise beneficially owns 368,741 Coeptis Therapeutics common shares. This total includes 49,500 shares held by CJC Investment Trust and 47,106 shares that are issuable under currently exercisable warrants, in addition to other directly held shares.

What role does CJC Investment Trust play in Chris Calise’s Coeptis Therapeutics (COEP) holdings?

CJC Investment Trust holds 49,500 Coeptis Therapeutics common shares included in Chris Calise’s beneficial ownership. The trust is described as an entity in which Mr. Calise is a control person, so those trust-held shares are reported as part of his overall beneficial holdings.

Are warrants included in Chris Calise’s reported Coeptis Therapeutics (COEP) ownership?

Yes. Chris Calise’s reported beneficial ownership includes 47,106 Coeptis Therapeutics common shares that are issuable under currently exercisable warrants. These warrant-based shares are counted alongside stock held directly and through CJC Investment Trust in his total 368,741-share beneficial position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calise Chris

(Last) (First) (Middle)

105 BRADFORD ROAD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		5,700	A	$10.56(1)	368,741	D(3)
Common stock	02/11/2026		A		3,250	A	$0(2)	368,741	D(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

3. Includes (i) 49,500 shares of common stock that are owned by CJC Investment Trust (a Trust in which Mr. Calise is a control person), and (ii) 47,106 shares of common stock that are issuable under currently exercisable warrants.

	/s/ Christopher Calise	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.